Outcome predictors for severe obsessive–compulsive patients in intensive residential treatment

Ackerman, 2002, Multivariate meta-analysis of controlled drug studies for obsessive–compulsive disorder, Journal of Clinical Psychopharmacology, 22, 309, 10.1097/00004714-200206000-00012 Ackerman, 1999, Side effects as predictors of drug response in obsessive–compulsive disorder, Journal of Clinical Psychopharmacology, 19, 459, 10.1097/00004714-199910000-00010 Ackerman, 1998, Clinical characteristics of response to fluoxetine treatment of obsessive–compulsive disorder, Journal of Clinical Psychopharmacology, 18, 185, 10.1097/00004714-199806000-00002 Ackerman, 1994, Predictors of treatment response in obsessive–compulsive disorder: multivariate analyses from a multicentre trial of clomipramine, Journal of Clinical Psychopharmacology, 14, 247, 10.1097/00004714-199408000-00004 Alarcon, 1993, A predictive study of OCD response to clomipramine, Journal of Clinical Psychopharmacology, 13, 210, 10.1097/00004714-199306000-00010 Alonso, 2001, Long-term follow-up and predictors of clinical outcome in obsessive–compulsive patients treated with serotonergic reuptake inhibitors and behavioral therapy, Journal of Clinical Psychiatry, 62, 535, 10.4088/JCP.v62n07a06 AuBuchon, 1994, Obsessive–compulsive patients with comorbid personality disorder: associated problems and response to a comprehensive behavior therapy, Journal of Clinical Psychiatry, 55, 448 Baer, 1992, Effect of axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive–compulsive disorder, Archives of General Psychiatry, 49, 862, 10.1001/archpsyc.1992.01820110026003 Ball, 1996, Symptom subtypes of obsessive–compulsive disorder in behavioral treatment studies: A quantitative review, Behavior Research and Therapy, 34, 47, 10.1016/0005-7967(95)00047-2 Beck, 1961, An inventory for measuring depression, Archives of General Psychiatry, 4, 561, 10.1001/archpsyc.1961.01710120031004 Blais, 1999, Development and initial validation of a brief mental health outcome measure, Journal of Personality Assessment, 73, 359, 10.1207/S15327752JPA7303_5 Burt, 2002, Outcome measurement in mood disorders, 164 Brody, 1998, FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder, Psychiatry Research, 84, 1, 10.1016/S0925-4927(98)00041-9 Buchanan, 1996, What predicts improvement and compliance during behavioral treatment of obsessive compulsive disorder?, Anxiety, 2, 22, 10.1002/(SICI)1522-7154(1996)2:1<22::AID-ANXI3>3.0.CO;2-F Carrasco, 1992, Treatment outcome of obsessive compulsive disorder with comorbid social phobia, Journal of Clinical Psychiatry, 53, 387 Cavedini, 1997, Predictive value of obsessive–compulsive personality disorder in antiobsessional pharmacologic treatment, European Neuropsychpharmacology, 7, 45, 10.1016/S0924-977X(96)00382-3 Charney, 1988, Serotonin function in obsessive–compulsive disorder: a comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects, Archives of General Psychiatry, 65, 177, 10.1001/archpsyc.1988.01800260095012 de Haan, 1997, Prediction of outcome and early vs. late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy, Acta Psychiatrica Scandinavica, 96, 354, 10.1111/j.1600-0447.1997.tb09929.x DeVeaugh-Geiss, 1990, Clinical predictors of treatment response in obsessive–compulsive disorder: Exploratory analyses from multicenter trials of clomipramine, Psychopharmacology Bulletin, 26, 54 Doge, 1993, Sex difference of rat brain monoamine metabolism under restraint stress, Japanese Journal of Legal Medicine, 47, 46 Douglass, 1995, Obsessive–compulsive disorder in a birth cohort of 18-year-olds: Prevalence and predictors, Journal of American Academey of Child and Adolescent Psychiatry, 34, 1424, 10.1097/00004583-199511000-00008 Drummond, 1993, The treatment of severe, chronic, resistant obsessive–compulsive disorder, British Journal of Psychiatry, 163, 223, 10.1192/bjp.163.2.223 Emmelkamp, 1981, Psychological treatment of obsessive–compulsive disorder: A follow-up four years after treatment, 1095 Erzegovesi, 2001, Clinical predictors of drug response in obsessive–compulsive disorder, Journal of Clinical Psychopharmacology, 21, 488, 10.1097/00004714-200110000-00006 Expert Consensus Treatment Guidelines for OCD, 1997, Journal of Clinical Psychiatry, 58, 65 Foa, 1983, Success and failure in the behavioral treatment of obsessive–compulsives, Journal of Consulting and Clinical Psychology, 51, 287, 10.1037/0022-006X.51.2.287 Goodman, 1993, Biological approaches to treatment-resistant obsessive–compulsive disorder, Journal of Clinical Psychiatry, 54, 16 Goodman, 1989, The Yale-Brown Obsessive Compulsive Scale. II. Validity, Archives of General Psychiatry, 46, 1012, 10.1001/archpsyc.1989.01810110054008 Goodman, 1989, The Yale-Brown Obsessive Compulsive Scale. I. Development, use and reliability, Archives of General Psychiatry, 46, 1006, 10.1001/archpsyc.1989.01810110048007 Harrell, 1985, Regression models for prognostic prediction: advantages, problems, and suggested solutions, Cancer Treatment Reports, 69, 1071 Hollander, 1997, A pharmacoeconomic and quality of life study of obsessive–compulsive disorder, CNS Spectrums, 2, 16, 10.1017/S1092852900011068 Hurley, 2002, Predicting treatment response in obsessive–compulsive disorder, Journal of Neuropsychiatry and Clinical Neurosciences, 14, 249, 10.1176/appi.neuropsych.14.3.249 Karayiorgou, 1999, Family-based association studies support a sexually-dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive–compulsive disorder, Biological Psychiatry, 45, 1178, 10.1016/S0006-3223(98)00319-9 Karayiorgou M, Altemus M, Galke BL, Goldman D, Murphy DL, Ott J, Gogos JA. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive–compulsive disorder. Paper presented at National Academy of Sciences of the United States of America, 1997. Kaplan, 1998 Keijsers, 1994, Predictors of treatment outcome in the behavioural treatment of obsessive–compulsive disorder, British Journal of Psychiatry, 165, 781, 10.1192/bjp.165.6.781 Koran, 2005, Mirtazapine for obsessive–compulsive disorder: an open trial followed by double-blind discontinuation, Journal of Clinical Psychiatry, 66, 515, 10.4088/JCP.v66n0415 Koran, 2000, Olanzapine augmentation for treatment-resistant obsessive–compulsive disorder, Journal of Clinical Psychiatry, 61, 514, 10.4088/JCP.v61n0709 Koran, 1996, Quality of life for patients with obsessive–compulsive disorder, American Journal of Psychiatry, 153, 783, 10.1176/ajp.153.6.783 Leonard, 1993, A 2- to 7-year follow-up study of 54 obsessive–compulsive children and adolescents, Archives of General Psychiatry, 50, 429, 10.1001/archpsyc.1993.01820180023003 Mallows, 1973, Some Comments on C(p), Technometrics, 15, 661, 10.2307/1267380 Mataix-Cols, 1999, Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive–compulsive disorder, American Journal of Psychiatry, 156, 1409, 10.1176/ajp.156.9.1409 Mataix-Cols, 2002, Obsessive–compulsive symptom dimensions as predictors of compliance with and response to behavior therapy: Results from a controlled trial, Psychotherapy and Psychosomatics, 71, 255, 10.1159/000064812 Mataix-Cols, 2002, Symptom stability in adult obsessive–compulsive disorder: data from a naturalistic two-year follow-up study, American Journal of Psychiatry, 159, 263, 10.1176/appi.ajp.159.2.263 Mathew, 2001, Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive-compulsive disorder, Depress Anxiety, 14, 199, 10.1002/da.1067 Morault, 1998, Improvement predictors in obsessive–compulsive disorder. An event-related potential study, Psychiatry Research, 81, 87, 10.1016/S0165-1781(98)00091-2 Mundo, 1999, Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: Is gender a predictive variable?, Biological Psychiatry, 45, 290, 10.1016/S0006-3223(98)00027-4 Mundt, 2002, The Work and Social Adjustment Scale: a simple measure of impairment in functioning, British Journal of Psychiatry, 180, 461, 10.1192/bjp.180.5.461 National Institute of Mental Health, 1985, CGI (Clinical Global Impression) Scale-NIMH, Psychopharmacology Bulletin, 21, 839 Neziroglu, 2004, Overvalued ideation as a predictor of fluvoxamine response in patients with obsessive–compulsive disorder, Psychiatry Research, 125, 53, 10.1016/j.psychres.2003.10.001 Piacentini, 2002, Open trial of cognitive behavior therapy for childhood obsessive–compulsive disorder, Journal of Anxiety Disorders, 16, 207, 10.1016/S0887-6185(02)00096-8 Pigott, 1997, Pharmacotherapy of OCD, International Review of Psychiatry, 9, 133, 10.1080/09540269775655 Rasmussen, 1994, The epidemiology and differential diagnosis of obsessive compulsive disorder, Journal of Clinical Psychiatry, 55, 5 Rauch, 2001, Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for obsessive compulsive disorder, Biological Psychiatry, 50, 659, 10.1016/S0006-3223(01)01188-X Ravizza, 1995, Predictors of drug treatment response in obsessive-compulsive disorder, Journal of Clinical Psychiatry, 56, 368 SAS Institute Inc., 1999 Saxena, 1999, Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder, Neuropsychopharmacology, 21, 683, 10.1016/S0893-133X(99)00082-2 S-PLUS 6.2 for Windows User’s Guide. Seattle: Insightful Corporation, 2001. SPSS 12.0 for Windows. Chicago: SPSS Inc., 2003. Stein, 2002, Obsessive–Compulsive disorder, Lancet, 360, 397, 10.1016/S0140-6736(02)09620-4 Stein, 2001, Predictors of response to pharmacotherapy with citalopram in obsessive–compulsive disorder, International Journal of Psychopharmacology, 16, 357, 10.1097/00004850-200111000-00007 Steiner M, Gergel IP, Wheadon DE. Predictors of response to paroxetine therapy in OCD. Presented at the annual meeting of the American Psychiatric Association: New York, 1996. Steketee, 2001, Effects of axis I and II comorbidity on behavior therapy outcome for obsessive–compulsive disorder and agoraphobia, Comprehensive Psychiatry, 42, 76, 10.1053/comp.2001.19746 Steketee, 1999 Steketee, 1997, Disability and family burden in obsessive–compulsive disorder, Canadian Journal of Psychiatry, 42, 919, 10.1177/070674379704200902 Steketee, 1999, Predictors of course in obsessive–compulsive disorder, Psychiatry Research, 89, 229, 10.1016/S0165-1781(99)00104-3 Steketee, 1993, Social support and treatment outcome of obsessive–compulsive disorder at 9-month follow-up, Behavioral Psychotherapy, 21, 81, 10.1017/S014134730001805X Stewart, 2005, Effectiveness of intensive residential treatment (IRT) for severe refractory obsessive–compulsive disorder, Journal of Psychiatric Research, 603, 10.1016/j.jpsychires.2005.01.004 Stewart, 2004, Long term outcome of pediatric obsessive compulsive disorder: A meta-analysis and qualitative review of the literature, Acta Psychiatrica Scandinavica, 110, 4, 10.1111/j.1600-0447.2004.00302.x Thase, 1994, Do depressed men and women respond similarly to cognitive behavior therapy, American Journal of Psychiatry, 151, 500, 10.1176/ajp.151.4.500 Thomsen, 1995, Obsessive–compulsive disorder in children and adolescents: predictors in childhood for long-term phenomenological course, Acta Psychiatrica Scandinavica, 92, 255, 10.1111/j.1600-0447.1995.tb09579.x Thornicroft, 1991, An in-patient behavioural psychotherapy unit. Description and audit, British Journal of Psychiatry, 158, 362, 10.1192/bjp.158.3.362 Willis, 1998, Inpatient and home-based treatment of obsessive–compulsive disorder, 583 Yovel I, Wilhelm S, Gershuny B, et al. The Obsessive–Compulsive Symptoms Rating Inventory: Development and Psychometric Analysis. In: 37th annual convention of the association for the advancement of behavior therapy, Boston, MA, 2003.